Arvinas Inc News - ARVN | ADVFN

Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

Get Started

Arvinas Inc (ARVN)

18.06

0.56

(3.23%)

Closed March 06 4:00PM

Delayed by 15 minutes

18.06

0.00

( 0.00% )

Pre Market: 8:55AM

Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

1
Next

Mr.Mister

Mr.Mister 2 days ago

Monksdream

Monksdream 6 months ago

ARVN at a bottom channel

Monksdream

Monksdream 1 year ago

ARVN new 52=week high

Monksdream

Monksdream 1 year ago

ARVN new 52 week high

Monksdream

Monksdream 1 year ago

ARVN new 52 week high

Monksdream

Monksdream 1 year ago

ARVN new 52 week high

crudeoil24

crudeoil24 4 years ago

ARVN up 138% > "Based on data to date, we believe ARV-471 is the most promising ER-targeting therapy in the clinic, showing early signs of efficacy, a favorable tolerability profile, and better ER degradation than that previously reported for fulvestrant, the current standard of care,” said Ron Peck, Ph.D., Chief Medical Officer at Arvinas. “It is exciting to see that ARV-110 continues to be active and well tolerated in what we believe is the most heavily pretreated patient population that has ever been studied with an AR-directed therapy. Our recently initiated ARDENT Phase 2 cohort expansion is specifically designed to investigate the potential of a precision medicine approach in molecularly defined, late-line patients with few available treatment options, while also fully characterizing the safety and activity of ARV-110 in earlier line patients irrespective of molecular profile, setting ARV-110 on a potential two-pronged registrational path.”

biocqr

biocqr 5 years ago

Advantages of PROTACs vs. inhibition...

message_id=152832655

G-lupo

G-lupo 5 years ago

Idk about that, I thought it had some resistance and kept going through, I think at this next convention their going to release some positive news. I’m so holy I didn’t sell at $30 which was ceiling I thought. Do have in a $35 limit sell thought if drops. Rebuy anything under $25

boo boo

boo boo 5 years ago

Starting to see a chink in the armor!

G-lupo

G-lupo 5 years ago

Possibly wall at 30.50

G-lupo

G-lupo 5 years ago

I feel people are going to start taking profits before $35 price target and give it a dip back.
Question is what is that dip price

boo boo

boo boo 5 years ago

The offering:

8-k

boo boo

boo boo 5 years ago

Benzinga 11/14/2019:

With a rating of Buy, Roth Capital initiated coverage on Arvinas Inc (NASDAQ:ARVN). The price target is set at $35.00 for Arvinas. In the third quarter, Arvinas showed an EPS of $0.21, compared to ($62.38) from the year-ago quarter. The current market cap for Arvinas is at $696.1 million. The stock has a 52-week-high of $28.96 and a 52-week-low of $10.19. Arvinas's stock last closed at $28.38 per share.

I might post a chart in about a week, well after everything plays out!

boo boo

boo boo 5 years ago

It doesn't have to be a PR:

#8

G-lupo

G-lupo 5 years ago

Thanks, I’m in it, thought $28 would be resistant and broke through looks may break $30

boo boo

boo boo 5 years ago

https://polsonnews.com/arvinas-inc-nasdaqarvn-receives-34-33-average-pt-from-brokerages/

G-lupo

G-lupo 5 years ago

When did they Do a price target announcement? I didn’t see that.

boo boo

boo boo 5 years ago

If I were in this one (I'm not), I'd be finding the exit on the price target announcement.

G-lupo

G-lupo 5 years ago

Arvn looking good, defintely see $26-27

G-lupo

G-lupo 5 years ago

What you mean IBD?

boo boo

boo boo 5 years ago

Not me. I look for the trade setup. Learned of this one from IBD and have been following...waiting. Missed the opportunity by 1 day. Would've, Should've, Could've...

G-lupo

G-lupo 5 years ago

I agree I own a decent amount, purchased from $22 down to $15.50. In for the long haul

boo boo

boo boo 5 years ago

Missing a trade and people who post a purchase at a specific price well after that price has passed.

The bottom of the prior range (July thru September) is resistance as far as I'm concerned and you have a couple important SMA's around there. And I agree that a break of $27 could lead to a higher price. Wouldn't be as confident if a press release occurred at the same time, but then again depends on what is said.

G-lupo

G-lupo 5 years ago

What are you talking about ?

Saw the rebound at $16, going to get probably Around $25-26, if gets there look for resistance to drop back. Like this stock and with more news if breaks $27 could see $60

boo boo

boo boo 5 years ago

Screwed this one up. More and better content on biotech values board. And no, I don't think this individual bought 'yesterday' and posted about it the day after. That's crap and not credible...POSER!

boo boo

boo boo 5 years ago

boo boo

boo boo 5 years ago

Price is at the 100 Lower Linear Regression channel. Do we consolidate here and eventually move north. No position...yet!

PennyStock Alert

PennyStock Alert 6 years ago

G-lupo

G-lupo 6 years ago

This stock very volatile, no rhyme or reason why it’s been up and down.

morokoy

morokoy 6 years ago

Las Vegas man 1st in world to use new experimental cancer drug, ARV 101.

https://www.reviewjournal.com/life/health/las-vegas-man-1st-in-world-to-use-new-experimental-cancer-drug-video-1654750/

Delayed Upgrade Clock